Murphy Nicole 4

What Happened

• Nicole Murphy, Head of Pharmaceutical Operations & Technology at Biogen, had derivative awards converted into 8,725 shares on Feb 6, 2026 (three conversions: 2,102; 1,940; 4,683 shares). To satisfy tax withholding, 3,339 of those shares were disposed at $201.18 each for total withholding of $671,740 (three dispositions: 1,017; 914; 1,408 shares).
• The conversions show an exercise/conversion price of $0.00, indicating settlement of restricted stock units or similar award rather than a cash exercise. The share sales were tax withholdings (code F), a routine transaction rather than an open-market investment decision.

Key Details

• Transaction date: Feb 6, 2026; Form 4 filed Feb 10, 2026 (timely within the required reporting window).
• Prices and values: withholding disposals at $201.18 per share; total tax withholding proceeds/value = $204,600 + $183,879 + $283,261 = $671,740.
• Shares converted (acquired): 8,725 total. Shares disposed for taxes: 3,339 total. Net increase in shares held from these events: 5,386 shares (8,725 − 3,339).
• Footnotes: F1 notes 166.6667 shares from the Biogen ESPP (3/31/2025). F2–F4 describe RSU vesting schedules (three equal annual installments beginning one year after grant dates in 2023, 2024 and 2025).
• Filing timeliness: Filed on Feb 10 for Feb 6 transactions — appears timely (not late).

Context

• The transactions appear to be settlement/conversion of equity awards (restricted stock units or similar) with a portion of the newly issued shares withheld/sold to cover required taxes — a common administrative step when awards vest. Because the disposals were tax withholdings, they do not necessarily signal the insider is reducing their long-term exposure to the company.